Norwegian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

meningococcal infections/nausea

Koblingen er lagret på utklippstavlen
9 resultater

Presenting features of meningococcal disease, public health messages and media publicity: are they consistent?

Bare registrerte brukere kan oversette artikler
Logg inn Registrer deg
OBJECTIVE To investigate whether the presenting features of meningococcal disease as promoted in public health awareness material and in the print media accurately reflect the clinical features in patients admitted to Auckland hospitals with meningococcal disease January 1998 to June

[Clinical characterization of cases with meningococcal disease by W135 group in Chile, 2012].

Bare registrerte brukere kan oversette artikler
Logg inn Registrer deg
BACKGROUND During 2012 in Chile, there were 60 cases of serogroup W135 meningococcal disease, which accounts for 57.7% of identified serogroup cases. OBJECTIVE To describe main clinical features of patients with serogroup W135 meningococcal disease confirmed in 2012. METHODS Descriptive study of

[Gastrointestinal symptoms with meningococcal infection. Emergence of Neisseria meningitidis serogroup W.]

Bare registrerte brukere kan oversette artikler
Logg inn Registrer deg
BACKGROUND Meningococcal disease usually presents as meningitis and/or septicaemia, but can also present as pneumonia or arthritis. Since 2000, a worldwide increase in meningococcal disease is reported which is caused by a new virulent clone of serogroup W (MenW:cc11). This subtype is more likely to
Atypical clinical presentations associated with group W meningococcal disease (MenW) are well-described and include pneumonia, septic arthritis, endocarditis and epiglottitis/supraglottitis. Following anecdotal reports of teenagers presenting with predominantly gastrointestinal symptoms, we

Notes from the Field: Meningococcal Disease in an International Traveler on Eculizumab Therapy - United States, 2015.

Bare registrerte brukere kan oversette artikler
Logg inn Registrer deg
On June 2, 2015, CDC was notified that a male airline passenger, aged 41 years, with a fever of 105.4°F, headache, nausea, photophobia, diarrhea, and vomiting, which began approximately 3 hours after departure, was arriving to San Francisco, California, on a flight from Frankfurt, Germany. His
Eculizumab has been developed as a breakthrough treatment for paroxysmal nocturnal hemoglobinuria (PNH). Not only for breakthroughs, eculizumab therapy is also known to increase the risk of invasive meningococcal infection. It has also been recently reported that, although rarely, administration of

Safety of meningococcal B vaccine (4CMenB) in adolescents in Australia

Bare registrerte brukere kan oversette artikler
Logg inn Registrer deg
Background: Four-component meningococcal B (4CMenB) vaccine is licensed in many countries but has had limited use in adolescents despite this age group being at increased risk of meningococcal disease.

Minocycline for prophylaxis of infection with Neisseria meningitidis: high rate of side effects in recipients.

Bare registrerte brukere kan oversette artikler
Logg inn Registrer deg
A high rate of side effects (mostly vestibular) was found among 83 people receiving prophylaxis with minocycline because of contact with a patient who had died of meningitis due to Neisseria meningitidis. Three groups of contacts received different lots of minocycline and different dosage regimens.

Eculizumab.

Bare registrerte brukere kan oversette artikler
Logg inn Registrer deg
OBJECTIVE The pharmacology, pharmacokinetics, indications, clinical efficacy, adverse effects, drug interactions, and dosage and administration of eculizumab are reviewed. CONCLUSIONS Eculizumab, a recombinant, humanized, monoclonal, immunoglobulin G antibody produced from murine myeloma cells, is
Bli med på
facebooksiden vår

Den mest komplette databasen med medisinske urter støttet av vitenskap

  • Fungerer på 55 språk
  • Urtekurer støttet av vitenskap
  • Urtegjenkjenning etter bilde
  • Interaktivt GPS-kart - merk urter på stedet (kommer snart)
  • Les vitenskapelige publikasjoner relatert til søket ditt
  • Søk medisinske urter etter deres effekter
  • Organiser dine interesser og hold deg oppdatert med nyheter, kliniske studier og patenter

Skriv inn et symptom eller en sykdom og les om urter som kan hjelpe, skriv en urt og se sykdommer og symptomer den brukes mot.
* All informasjon er basert på publisert vitenskapelig forskning

Google Play badgeApp Store badge